fda compounding semaglutide enforcement november 2025 news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Important Update: Changes to Compounded

You might also feel numbness or tingling in the hands and feet , have trouble walking, or notice changes in thinking

Phase Three: Maintenance If you reach your goal weight, the Noom Med Care Team will help you plan next steps

Many patients reduce their dose or quit entirely because of GI discomfort

Farxiga (dapagliflozin) is one of the most well-known pharmaceuticals in the SGLT2 inhibitor class, which is one of the more recent pharmacological classes for treating Type 2 diabetes

Trends Endocrin

Among chemotherapeutic agents used, Doxorubicin and Cyclophosphamide are widely used in combination for solid tumor management (Christie et al